摘要
目的:观察雷珠单抗辅助玻璃体切割+全视网膜光凝(PRP)+小梁切除术治疗新生血管性青光眼(NVG)的临床疗效。方法:回顾性分析2017-03/2018-10收治的NVG患者44例44眼,采用玻璃体腔内注射雷珠单抗+玻璃体切割+PRP+小梁切除手术治疗的患者22例22眼(A组),采用玻璃体腔内注射雷珠单抗+小梁切除+PRP治疗的患者22例22眼(B组)。术后随访6mo,观察患者视力、眼压、眼压控制率、新生血管及并发症等情况。结果:治疗前两组患者眼压无差异(46.2±9.41mmHg vs 49.1±10.15mmHg,P>0.05),治疗后1wk,1、6mo A组患者眼压均低于B组(P<0.05)。治疗后6mo,A组视力、眼压控制率(95%)、新生血管消退情况(91%)均优于B组(P<0.05),但随访期间两组患者并发症发生率无差异(P>0.05)。结论:雷珠单抗辅助玻璃体切割+PRP+小梁切除术治疗NVG安全有效,可稳定持久地控制眼压,改善部分患者视力。
·AIM:To observe the clinical effect of ranibizumab injection combined with vitrectomy,panretinal photocoagulation(PRP)and trabeculectomy in the treatment of neovascular glaucoma(NVG).·METHODS:Retrospective study.From March 2017 to October 2018,44 NVG patients(44 eyes)were treated,22 patients(22 eyes)were treated with intravitreal injection of ranibizumab+vitrectomy+PRP+trabeculectomy(group A),and 22 patients(22 eyes)were treated with intravitreal injection of ranibizumab+trabeculectomy+PRP(group B).The patients were followed up for 6mo,the visual acuity,intraocular pressure(IOP),IOP control rate,neovascularization and complications were observed.·RESULTS:There was no significant difference in IOP between the two groups before treatment(46.2±9.41mmHg vs 49.1±10.15mmHg,P>0.05).The IOP of group A was lower than that of group B at 1wk,1mo and 6mo after treatment(P<0.05).6mo after treatment,the visual acuity,IOP control rate(95%)and neovascularization regression(91%)in group A were better than those in group B(P<0.05),but there was no difference in the incidence of complications between the two groups during the follow-up period(P>0.05).·CONCLUSION:It is safe and effective to treat NVG with intravitreal ranibizumab injection combined with vitrectomy,PRP and trabeculectomy,which can control IOP steadily and improve visual acuity of some patients.
作者
苏锐锋
苏畅
赵敏
谭小波
Rui-Feng Su;Chang Su;Min Zhao;Xiao-Bo Tan(Department of Ophthalmology, the Affiliated Hospital of Chengde Medical College, Chengde 067000, Hebei Province, China)
出处
《国际眼科杂志》
CAS
北大核心
2020年第8期1431-1434,共4页
International Eye Science
基金
河北省自然科学基金项目(No.H2015406054)。
